Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Prospective, Open-Label, Parallel Study Evaluating the Effect of an Adjunctive Anti-Seizure Medication Using a Glutamatergic Modulator in Patients With Focal Epilepsy and High-Grade Glioma

NCT04650204 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04650204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04650204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Prospective, Open-Label, Parallel Study Evaluating the Effect of an Adjunctive Anti-Seizure Medication Using a Glutamatergic Modulator in Patients With Focal Epilepsy and High-Grade Glioma
Lead sponsor
Mayo Clinic
Phase
Phase 4
Overall status
Terminated
Start date
December 4, 2020
Completion date
April 30, 2023
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intractable epilepsy, malignant glioma, seizure disorder, who grade 2 glioma, who grade 3 glioma